Compugen (NASDAQ:CGEN) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Compugen (NASDAQ:CGEN) in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a $4.00 target price on the biotechnology company’s stock.

Separately, Weiss Ratings upgraded shares of Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $5.00.

Compugen Trading Down 2.8%

Shares of CGEN opened at $2.07 on Monday. The company has a market cap of $195.72 million, a PE ratio of 5.45 and a beta of 2.78. The stock has a 50-day moving average price of $2.44 and a 200-day moving average price of $2.43. Compugen has a 12-month low of $1.43 and a 12-month high of $3.23.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.60 million during the quarter, compared to analyst estimates of $1.28 million. Compugen had a return on equity of 42.57% and a net margin of 47.56%. During the same quarter in the previous year, the firm earned ($0.08) earnings per share. As a group, analysts predict that Compugen will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in Compugen by 12.1% during the first quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock valued at $3,478,000 after purchasing an additional 176,088 shares in the last quarter. WINTON GROUP Ltd boosted its holdings in shares of Compugen by 26.0% in the 2nd quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company’s stock worth $422,000 after purchasing an additional 40,614 shares in the last quarter. Platform Technology Partners increased its position in shares of Compugen by 10.0% during the 1st quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 5,000 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of Compugen during the 2nd quarter valued at about $110,000. Finally, Glenmede Trust Co. NA increased its position in shares of Compugen by 187.5% during the 1st quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 22,500 shares during the last quarter. Institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biotechnology company focused on developing therapeutics for cancer and other diseases involving the immune system. The company uses computational biology and artificial intelligence-driven approaches to identify potential drug targets and develop antibody-based immunotherapies designed to restore or enhance the immune system’s ability to recognize and attack tumors.

Compugen’s pipeline has included investigational immune checkpoint and immuno-oncology programs, including COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT.